Brief: Apellis Pharmaceuticals Updated U.S. Prescribing Information For Syfovre

Apellis Pharmaceuticals

01/12/2023 14:13

Dec 1 (Reuters) - Apellis Pharmaceuticals Inc  APLS.O :
    * APELLIS PHARMACEUTICALS INC: ON NOV 30, CO UPDATED U.S.
PRESCRIBING INFORMATION FOR SYFOVRE(REG) (PEGCETACOPLAN)
    * APELLIS -USPI TO NOW INCLUDE INFORMATION REGARDING RARE
EVENTS
OF RETINAL VASCULITIS WITH/WITHOUT OCCLUSION IN PATIENTS TREATED
WITH SYFOVRE
    * APELLIS PHARMACEUTICALS INC: ESTIMATED RATE OF EVENTS OF
RETINAL
VASCULITIS REMAINS RARE AT 0.01% PER INJECTION
    * APELLIS PHARMACEUTICALS INC: MORE THAN 120,000 INJECTIONS
ESTIMATED TO HAVE BEEN ADMINISTERED AS OF NOV 18


Further company coverage:  APLS.O 

 ((Reuters.Briefs@thomsonreuters.com;))